Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
BioCentury | Aug 27, 2021
Distillery Therapeutics
CRISPR-Cas9 deletion of mutant APP to treat Alzheimer’s
BioCentury | Apr 7, 2021
Distillery Therapeutics
RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s
DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of
INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of
BioCentury | Feb 11, 2020
Product Development
Alzheimer’s prevention replays the same amyloid failures as the treatment setting
Lilly’s solanezumab, Roche’s gantenerumab miss DIAN-TU endpoint in presymptomatic AD patients
BioCentury | May 4, 2019
Product Development
How the amyloid hypothesis holds its grip
Why pharmas can’t let go of the amyloid hypothesis of Alzheimer’s disease
BioCentury | Jan 4, 2019
Tools & Techniques
Making AD mice as diverse as patients
How adding genetic diversity to Alzheimer’s mice could help define responders
Items per page:
1 - 10 of 53